Article Information
History
- September 12, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Hanmeng Xu1,
- Camilla Aparicio, MD2,
- Aanchal Wats, MD, MPH2,
- Barbara L. Araujo2,
- Virginia E. Pitzer, ScD1,
- Joshua L. Warren3,
- Eugene D. Shapiro, MD1,2,
- Linda M. Niccolai, PhD1,
- Daniel M. Weinberger, PhD1,* and
- Carlos R. Oliveira, MD, PhD1,2,4,#,*
- 1Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
- 2Department of Pediatrics, Section of Infectious Diseases and Global Health, Yale School of Medicine, New Haven, CT, USA
- 3Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA
- 4Department of Biostatistics, Section of Health Informatics, Yale School of Public Health, New Haven, CT, USA
- 5Department of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT, USA
- ↵#Corresponding author: Carlos R. Oliveira, Address: 464 Congress Avenue, Suite 204, New Haven, CT 06520, Phone: 203-785-5474, carlos.oliveira{at}yale.edu
↵* contributed equally as co-senior authors.
Posted September 12, 2024.
Real-World Effectiveness of Nirsevimab Against Respiratory Syncytial Virus: A Test-Negative Case-Control Study
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos